Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash & Equivalents (2018 - 2025)

Black Diamond Therapeutics' Cash & Equivalents history spans 6 years, with the latest figure at $21.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 42.39% year-over-year to $21.0 million; the TTM value through Dec 2025 reached $21.0 million, down 42.39%, while the annual FY2025 figure was $21.0 million, 42.39% down from the prior year.
  • Cash & Equivalents reached $21.0 million in Q4 2025 per BDTX's latest filing, down from $30.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $98.4 million in Q1 2025 to a low of $14.1 million in Q1 2021.
  • Average Cash & Equivalents over 3 years is $36.0 million, with a median of $30.9 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: plummeted 96.05% in 2021, then skyrocketed 287.16% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $46.6 million in 2021, then decreased by 21.81% to $36.4 million in 2024, then crashed by 42.39% to $21.0 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Cash & Equivalents are $21.0 million (Q4 2025), $30.9 million (Q3 2025), and $30.0 million (Q2 2025).